Tiff Caza
@glombandit.bsky.social
I am a kidney pathologist and researcher seeking personal and professional growth. I work at Arkana Labs, but posts are my own opinions.
Reposted by Tiff Caza
@nephrosharma.bsky.social and @glombandit.bsky.social
sat down with Dr. Salil Parikh, a radiologist who helped his facility improve their adequacy rates significantly, to discuss one possible blueprint for better renal biopsies. #nephsky #radiology
Listen to the conversation here:
sat down with Dr. Salil Parikh, a radiologist who helped his facility improve their adequacy rates significantly, to discuss one possible blueprint for better renal biopsies. #nephsky #radiology
Listen to the conversation here:
Glom Goals: A Blueprint for Better Renal Biopsies
YouTube video by Arkana Laboratories
www.youtube.com
October 30, 2025 at 1:08 PM
@nephrosharma.bsky.social and @glombandit.bsky.social
sat down with Dr. Salil Parikh, a radiologist who helped his facility improve their adequacy rates significantly, to discuss one possible blueprint for better renal biopsies. #nephsky #radiology
Listen to the conversation here:
sat down with Dr. Salil Parikh, a radiologist who helped his facility improve their adequacy rates significantly, to discuss one possible blueprint for better renal biopsies. #nephsky #radiology
Listen to the conversation here:
Reposted by Tiff Caza
IgA Vasculitis
A kidney biopsy is mandatory in patients with persistent proteinuria ≥0.5 g/day for more than 4 weeks, impaired kidney function, or suspicion of rapidly progressive glomerulonephritis (RPGN).
#NephJC
A kidney biopsy is mandatory in patients with persistent proteinuria ≥0.5 g/day for more than 4 weeks, impaired kidney function, or suspicion of rapidly progressive glomerulonephritis (RPGN).
#NephJC
October 29, 2025 at 1:43 AM
IgA Vasculitis
A kidney biopsy is mandatory in patients with persistent proteinuria ≥0.5 g/day for more than 4 weeks, impaired kidney function, or suspicion of rapidly progressive glomerulonephritis (RPGN).
#NephJC
A kidney biopsy is mandatory in patients with persistent proteinuria ≥0.5 g/day for more than 4 weeks, impaired kidney function, or suspicion of rapidly progressive glomerulonephritis (RPGN).
#NephJC
Reposted by Tiff Caza
The evidence of immunomodulatory effects of steroids and Nefecon comes from the following trials. High dose steroids treatment suffered from complications like infections. Nefecon, however, still showed similar systemic side-effects of other oral steroids.
#NephJC
#NephJC
October 29, 2025 at 1:20 AM
The evidence of immunomodulatory effects of steroids and Nefecon comes from the following trials. High dose steroids treatment suffered from complications like infections. Nefecon, however, still showed similar systemic side-effects of other oral steroids.
#NephJC
#NephJC
Reposted by Tiff Caza
Treatment Approach: 💊
Novel therapies for IgAN have shifted the paradigm to a bi-pronged approach.
a) Generic responses to HTN/proteinuria
b) Fundamental drivers of nephron loss by reducing the formation of aberrant IgA molecules & the maladaptive mechanisms that contribute to CKD. #NephJC
Novel therapies for IgAN have shifted the paradigm to a bi-pronged approach.
a) Generic responses to HTN/proteinuria
b) Fundamental drivers of nephron loss by reducing the formation of aberrant IgA molecules & the maladaptive mechanisms that contribute to CKD. #NephJC
October 29, 2025 at 1:18 AM
Treatment Approach: 💊
Novel therapies for IgAN have shifted the paradigm to a bi-pronged approach.
a) Generic responses to HTN/proteinuria
b) Fundamental drivers of nephron loss by reducing the formation of aberrant IgA molecules & the maladaptive mechanisms that contribute to CKD. #NephJC
Novel therapies for IgAN have shifted the paradigm to a bi-pronged approach.
a) Generic responses to HTN/proteinuria
b) Fundamental drivers of nephron loss by reducing the formation of aberrant IgA molecules & the maladaptive mechanisms that contribute to CKD. #NephJC
Reposted by Tiff Caza
Global Implementation of IgAN 2025 guidelines:
#NephJC
As we learn more and develop new treatments, it is important to try to make these available to a wide population of patients. Including low-income patients in future studies might allow for at least some access to cutting edge therapies.
#NephJC
As we learn more and develop new treatments, it is important to try to make these available to a wide population of patients. Including low-income patients in future studies might allow for at least some access to cutting edge therapies.
October 29, 2025 at 1:09 AM
Global Implementation of IgAN 2025 guidelines:
#NephJC
As we learn more and develop new treatments, it is important to try to make these available to a wide population of patients. Including low-income patients in future studies might allow for at least some access to cutting edge therapies.
#NephJC
As we learn more and develop new treatments, it is important to try to make these available to a wide population of patients. Including low-income patients in future studies might allow for at least some access to cutting edge therapies.
Reposted by Tiff Caza
First things first — where the story starts!
Time to unpack the 4-hit hypothesis of IgA nephropathy — understanding each step opens doors to new treatments. #NephJC
Time to unpack the 4-hit hypothesis of IgA nephropathy — understanding each step opens doors to new treatments. #NephJC
October 29, 2025 at 1:07 AM
First things first — where the story starts!
Time to unpack the 4-hit hypothesis of IgA nephropathy — understanding each step opens doors to new treatments. #NephJC
Time to unpack the 4-hit hypothesis of IgA nephropathy — understanding each step opens doors to new treatments. #NephJC
Reposted by Tiff Caza
🎨Beautiful visual abstract by Dr Natalia Nombera @roxnonna23.bsky.social #NephJC
www.nephjc.com/news/...
www.nephjc.com/news/...
October 29, 2025 at 1:04 AM
🎨Beautiful visual abstract by Dr Natalia Nombera @roxnonna23.bsky.social #NephJC
www.nephjc.com/news/...
www.nephjc.com/news/...
Reposted by Tiff Caza
There is a 13-year gap between the approval of new drugs for use in adults and their approval in children. Could extrapolation accelerate clinical trials in pediatric nephrology? Read more in #ASNKidneyNews kidney.pub/KN1710-10
October 17, 2025 at 7:00 PM
There is a 13-year gap between the approval of new drugs for use in adults and their approval in children. Could extrapolation accelerate clinical trials in pediatric nephrology? Read more in #ASNKidneyNews kidney.pub/KN1710-10
Reposted by Tiff Caza
Did you know inadequate renal biopsies are on the rise?
Recently, Dr. Shree Sharma and @glombandit.bsky.social sat down with Dr. Vandana Niyyar, @nephrowhitt.bsky.social, and @juancarlosqvelez.bsky.social to discuss renal biopsy adequacy and understand why it matters.
Listen to the conversation:
Recently, Dr. Shree Sharma and @glombandit.bsky.social sat down with Dr. Vandana Niyyar, @nephrowhitt.bsky.social, and @juancarlosqvelez.bsky.social to discuss renal biopsy adequacy and understand why it matters.
Listen to the conversation:
Renal biopsy adequacy
open.spotify.com
August 28, 2025 at 9:22 PM
Did you know inadequate renal biopsies are on the rise?
Recently, Dr. Shree Sharma and @glombandit.bsky.social sat down with Dr. Vandana Niyyar, @nephrowhitt.bsky.social, and @juancarlosqvelez.bsky.social to discuss renal biopsy adequacy and understand why it matters.
Listen to the conversation:
Recently, Dr. Shree Sharma and @glombandit.bsky.social sat down with Dr. Vandana Niyyar, @nephrowhitt.bsky.social, and @juancarlosqvelez.bsky.social to discuss renal biopsy adequacy and understand why it matters.
Listen to the conversation:
Reposted by Tiff Caza
In the latest episode of Visiting Joel, our visiting scholar, Dr. Evgeniya Pasternak, works with @glombandit.bsky.social on a research article. #pathresident #renalpath #renalrotation
Here's a link to the latest episode:
Here's a link to the latest episode:
Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.
youtu.be
August 4, 2025 at 5:02 PM
In the latest episode of Visiting Joel, our visiting scholar, Dr. Evgeniya Pasternak, works with @glombandit.bsky.social on a research article. #pathresident #renalpath #renalrotation
Here's a link to the latest episode:
Here's a link to the latest episode:
Reposted by Tiff Caza
Up next! ☀️📚 We're taking a short break from trials, but don’t go far— #NephJC Summer Book Club is back!
We’ll be diving into “Everything is Tuberculosis”—a powerful, thought-provoking read. Join the conversation soon! 📖
We’ll be diving into “Everything is Tuberculosis”—a powerful, thought-provoking read. Join the conversation soon! 📖
August 6, 2025 at 1:55 AM
Up next! ☀️📚 We're taking a short break from trials, but don’t go far— #NephJC Summer Book Club is back!
We’ll be diving into “Everything is Tuberculosis”—a powerful, thought-provoking read. Join the conversation soon! 📖
We’ll be diving into “Everything is Tuberculosis”—a powerful, thought-provoking read. Join the conversation soon! 📖
Reposted by Tiff Caza
T3j
🧘 eGFRdiff is weakly/not affected by
🚫 Fat free lean muscle mass
🚫 Inflammation
🚫 Shrunken pore syndrome
🚫 Obesity
💡 This lack of alteration due to systemic issues makes eGFRdiff attractive for use in a wide variety of patients. #NephJC
🧘 eGFRdiff is weakly/not affected by
🚫 Fat free lean muscle mass
🚫 Inflammation
🚫 Shrunken pore syndrome
🚫 Obesity
💡 This lack of alteration due to systemic issues makes eGFRdiff attractive for use in a wide variety of patients. #NephJC
July 23, 2025 at 1:50 AM
T3j
🧘 eGFRdiff is weakly/not affected by
🚫 Fat free lean muscle mass
🚫 Inflammation
🚫 Shrunken pore syndrome
🚫 Obesity
💡 This lack of alteration due to systemic issues makes eGFRdiff attractive for use in a wide variety of patients. #NephJC
🧘 eGFRdiff is weakly/not affected by
🚫 Fat free lean muscle mass
🚫 Inflammation
🚫 Shrunken pore syndrome
🚫 Obesity
💡 This lack of alteration due to systemic issues makes eGFRdiff attractive for use in a wide variety of patients. #NephJC
Reposted by Tiff Caza
T2f
Let's deep into the prospective analysis 🥽
For each 10 mL/min ↑ in eGFRdiff
🚨20% ↓ mortality risk (AHR 0.80 [95% CI: 0.74–0.88])
🚨17% ↓ HF risk (AHR 0.83 [95% CI: 0.73–0.94])
✅ Association held after adjustment for muscle mass & filtration markers.
What do we think? #NephJC
Let's deep into the prospective analysis 🥽
For each 10 mL/min ↑ in eGFRdiff
🚨20% ↓ mortality risk (AHR 0.80 [95% CI: 0.74–0.88])
🚨17% ↓ HF risk (AHR 0.83 [95% CI: 0.73–0.94])
✅ Association held after adjustment for muscle mass & filtration markers.
What do we think? #NephJC
July 23, 2025 at 1:32 AM
T2f
Let's deep into the prospective analysis 🥽
For each 10 mL/min ↑ in eGFRdiff
🚨20% ↓ mortality risk (AHR 0.80 [95% CI: 0.74–0.88])
🚨17% ↓ HF risk (AHR 0.83 [95% CI: 0.73–0.94])
✅ Association held after adjustment for muscle mass & filtration markers.
What do we think? #NephJC
Let's deep into the prospective analysis 🥽
For each 10 mL/min ↑ in eGFRdiff
🚨20% ↓ mortality risk (AHR 0.80 [95% CI: 0.74–0.88])
🚨17% ↓ HF risk (AHR 0.83 [95% CI: 0.73–0.94])
✅ Association held after adjustment for muscle mass & filtration markers.
What do we think? #NephJC
Reposted by Tiff Caza
T0f
So why does this matter?
A more negative eGFRdiff (eGFRcr > eGFRcys) is linked to:
🫀 Cardiovascular disease
🧬 Frailty
💓 Heart failure
⚰️ Mortality
#NephJC
So why does this matter?
A more negative eGFRdiff (eGFRcr > eGFRcys) is linked to:
🫀 Cardiovascular disease
🧬 Frailty
💓 Heart failure
⚰️ Mortality
#NephJC
July 23, 2025 at 1:14 AM
T0f
So why does this matter?
A more negative eGFRdiff (eGFRcr > eGFRcys) is linked to:
🫀 Cardiovascular disease
🧬 Frailty
💓 Heart failure
⚰️ Mortality
#NephJC
So why does this matter?
A more negative eGFRdiff (eGFRcr > eGFRcys) is linked to:
🫀 Cardiovascular disease
🧬 Frailty
💓 Heart failure
⚰️ Mortality
#NephJC
Reposted by Tiff Caza
T0e
But muscle mass isn’t the whole story.
🧨 Factors contributing to eGFRdiff include:
Chronic inflammation
Endothelial dysfunction
Shrunken pore syndrome
Obesity
Smoking
Corticosteroids
Which others do you consider? #NephJC
But muscle mass isn’t the whole story.
🧨 Factors contributing to eGFRdiff include:
Chronic inflammation
Endothelial dysfunction
Shrunken pore syndrome
Obesity
Smoking
Corticosteroids
Which others do you consider? #NephJC
July 23, 2025 at 1:13 AM
T0e
But muscle mass isn’t the whole story.
🧨 Factors contributing to eGFRdiff include:
Chronic inflammation
Endothelial dysfunction
Shrunken pore syndrome
Obesity
Smoking
Corticosteroids
Which others do you consider? #NephJC
But muscle mass isn’t the whole story.
🧨 Factors contributing to eGFRdiff include:
Chronic inflammation
Endothelial dysfunction
Shrunken pore syndrome
Obesity
Smoking
Corticosteroids
Which others do you consider? #NephJC
Reposted by Tiff Caza
T0c
eGFRdiff is now recognized by KDIGO 2024, which recommends using both creatinine & cystatin C to estimate GFR (practice point 1.2.3.1).
But why do these values differ in the first place? Let’s dig in. 🔍 #NephJC
eGFRdiff is now recognized by KDIGO 2024, which recommends using both creatinine & cystatin C to estimate GFR (practice point 1.2.3.1).
But why do these values differ in the first place? Let’s dig in. 🔍 #NephJC
July 23, 2025 at 1:11 AM
T0c
eGFRdiff is now recognized by KDIGO 2024, which recommends using both creatinine & cystatin C to estimate GFR (practice point 1.2.3.1).
But why do these values differ in the first place? Let’s dig in. 🔍 #NephJC
eGFRdiff is now recognized by KDIGO 2024, which recommends using both creatinine & cystatin C to estimate GFR (practice point 1.2.3.1).
But why do these values differ in the first place? Let’s dig in. 🔍 #NephJC
Reposted by Tiff Caza
On 7/22/25 at 9pm EST only on Bluesky!
#NephSky #MedSky join us for a lively discussion.
We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it. #NephJC
www.nephjc.com/news/egfrdiff
#NephSky #MedSky join us for a lively discussion.
We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it. #NephJC
www.nephjc.com/news/egfrdiff
Mind The Gap: When eGFR Creatinine and Cystatin C Disagree — NephJC
This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).
www.nephjc.com
July 21, 2025 at 11:31 AM
On 7/22/25 at 9pm EST only on Bluesky!
#NephSky #MedSky join us for a lively discussion.
We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it. #NephJC
www.nephjc.com/news/egfrdiff
#NephSky #MedSky join us for a lively discussion.
We're debating eGFRdiff (the gap that is sometimes present between the eGFR of cystatin C and creatinine). What does it mean, what causes it and what you should do about it. #NephJC
www.nephjc.com/news/egfrdiff
Lupus nephritis - this one is going out to Rush Nephrology 🎨@nephrowhitt.bsky.social
July 15, 2025 at 10:43 PM
Lupus nephritis - this one is going out to Rush Nephrology 🎨@nephrowhitt.bsky.social
Reposted by Tiff Caza
Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy
bit.ly/4ccCs4H #OpenAccess
#VisualAbstract
bit.ly/4ccCs4H #OpenAccess
#VisualAbstract
July 12, 2025 at 10:02 PM
Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy
bit.ly/4ccCs4H #OpenAccess
#VisualAbstract
bit.ly/4ccCs4H #OpenAccess
#VisualAbstract
Reposted by Tiff Caza
Urine CXCL-9, now in immune checkpoint inhibitor AIN! In @kidneyint.bsky.social
www.kidney-international.org/article/S008...
www.kidney-international.org/article/S008...
Urinary C-X-C-motif ligand 9 (CXCL9) in immune checkpoint inhibitor-associated acute interstitial nephritis
Immune checkpoint inhibitor-associated acute interstitial nephritis presents significant
clinical challenges. There are no reliable non-invasive biomarkers and kidney biopsy
remains the gold standard ...
www.kidney-international.org
June 26, 2025 at 2:02 PM
Urine CXCL-9, now in immune checkpoint inhibitor AIN! In @kidneyint.bsky.social
www.kidney-international.org/article/S008...
www.kidney-international.org/article/S008...
Reposted by Tiff Caza
June 26, 2025 at 1:58 PM
Reposted by Tiff Caza
T3f: #NephJC
👉Effective nudges require personalization + clear action steps
⚠️ Risk of becoming full "change-oriented" interventions
♻️ Change models: Create urgency → Communicate → Implement → Sustain
👉Effective nudges require personalization + clear action steps
⚠️ Risk of becoming full "change-oriented" interventions
♻️ Change models: Create urgency → Communicate → Implement → Sustain
June 25, 2025 at 1:45 AM
T3f: #NephJC
👉Effective nudges require personalization + clear action steps
⚠️ Risk of becoming full "change-oriented" interventions
♻️ Change models: Create urgency → Communicate → Implement → Sustain
👉Effective nudges require personalization + clear action steps
⚠️ Risk of becoming full "change-oriented" interventions
♻️ Change models: Create urgency → Communicate → Implement → Sustain
Reposted by Tiff Caza
👉We all need little nudges to do the right thing.
Join us 6/24/25 at 9pm EST as we chat about E-Nudges to improve goal directed medical therapy (GDMT) in CKD. #NephJC #NephSky
Blog by @nephroseeker.medsky.social @dramiliflores.bsky.social @husamjz.bsky.social
www.nephjc.com/news/nudge-ckd
Join us 6/24/25 at 9pm EST as we chat about E-Nudges to improve goal directed medical therapy (GDMT) in CKD. #NephJC #NephSky
Blog by @nephroseeker.medsky.social @dramiliflores.bsky.social @husamjz.bsky.social
www.nephjc.com/news/nudge-ckd
Are E-Nudges Enough to Push Guideline-Based CKD Therapy? — NephJC
This week, we will discuss a registry trial: can a nationwide nudge fix a CKD treatment gap?
www.nephjc.com
June 24, 2025 at 2:42 AM
👉We all need little nudges to do the right thing.
Join us 6/24/25 at 9pm EST as we chat about E-Nudges to improve goal directed medical therapy (GDMT) in CKD. #NephJC #NephSky
Blog by @nephroseeker.medsky.social @dramiliflores.bsky.social @husamjz.bsky.social
www.nephjc.com/news/nudge-ckd
Join us 6/24/25 at 9pm EST as we chat about E-Nudges to improve goal directed medical therapy (GDMT) in CKD. #NephJC #NephSky
Blog by @nephroseeker.medsky.social @dramiliflores.bsky.social @husamjz.bsky.social
www.nephjc.com/news/nudge-ckd
Reposted by Tiff Caza
Check the insightful #NephJC summary by @nephroseeker.medsky.social @dramiliflores.bsky.social,
http://www.nephjc.co...
http://www.nephjc.co...
Advance-HTN: Return of the systolic order – Lorundrostat’s role in restoring balance — NephJC
This week, we will discuss a NEJM trial on uncontrolled hypertension:
lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark
side driving resistance.
www.nephjc.com
May 28, 2025 at 1:04 AM
Check the insightful #NephJC summary by @nephroseeker.medsky.social @dramiliflores.bsky.social,
http://www.nephjc.co...
http://www.nephjc.co...